Suppr超能文献

欧洲白内障与屈光手术医师学会(ESCRS)关于白内障手术后预防眼内炎的研究:一项欧洲多中心研究主要结果的初步报告

ESCRS study of prophylaxis of postoperative endophthalmitis after cataract surgery: Preliminary report of principal results from a European multicenter study.

作者信息

Barry Peter, Seal David V, Gettinby George, Lees Fiona, Peterson Magnus, Revie Crawford W

机构信息

European Society of Cataract & Refractive Surgeons, Dublin, Ireland.

出版信息

J Cataract Refract Surg. 2006 Mar;32(3):407-10. doi: 10.1016/j.jcrs.2006.02.021.

Abstract

PURPOSE

To report results in the European Society of Cataract & Refractive Surgeons (ESCRS) multicenter study of the prophylaxis of endophthalmitis after cataract surgery.

SETTING

Twenty-four ophthalmology units and eye clinics in Austria, Belgium, Germany, Italy, Poland, Portugal, Spain, Turkey, and the United Kingdom, with an administrative office in Ireland, coordinating center in England, and data management and statistical unit in Scotland.

METHODS

This partially masked randomized placebo-controlled multinational clinical study to evaluate prospectively the prophylactic effect of intracameral cefuroxime injection and/or perioperative levofloxacin eyedrops on the incidence of endophthalmitis after phacoemulsification cataract surgery began in September 2003 and was terminated early in January 2006. The study used random allocation of patients in a 2 x 2 factorial design.

RESULTS

By the end of 2005, complete follow-up records had been received for 13 698 study patients. Such a clear beneficial effect from the use of intracameral cefuroxime had been observed that it was agreed it would be unethical to continue the study and to wait for the completion of all follow-up procedures before reporting this important result. If total reported cases of endophthalmitis are considered, the incidence rate observed in those treatment groups not receiving cefuroxime prophylaxis (23 cases in 6862 patients) was almost 5 times as high (odds ratio [OR], 4.59; 95% confidence interval [CI], 1.74-12.08; P = .002) as that in the groups receiving this treatment (5 cases in 6836 patients). If only cases proved to be due to infection are considered, the rate was more than 5 times as high (OR, 5.32; 95% CI, 1.55-18.26; P = .008) in the treatment groups not receiving cefuroxime. Although the use of perioperative levofloxacin eyedrops as prophylaxis was also associated with a reduction in the observed incidence rate of postoperative endophthalmitis, this effect was smaller and was not statistically significant, whether total reported cases or only cases proven to be due to infection are used in calculating the rates. As not all follow-up procedures are complete, it is possible that further cases of endophthalmitis may be reported; however, it is not expected that this will alter the main conclusion. Nevertheless, it is anticipated that successful completion of follow-up procedures in all patients will increase the total number in the study to approximately 16,000.

CONCLUSION

Intracameral cefuroxime administered at the time of surgery significantly reduced the risk for developing endophthalmitis after cataract surgery.

摘要

目的

报告欧洲白内障与屈光手术医师学会(ESCRS)关于白内障手术后眼内炎预防的多中心研究结果。

设置

奥地利、比利时、德国、意大利、波兰、葡萄牙、西班牙、土耳其和英国的24个眼科单位及眼科诊所,行政办公室位于爱尔兰,协调中心位于英格兰,数据管理与统计单位位于苏格兰。

方法

这项部分设盲的随机安慰剂对照多国临床研究,旨在前瞻性评估前房注射头孢呋辛和/或围手术期使用左氧氟沙星滴眼液对白内障超声乳化术后眼内炎发生率的预防效果。该研究于2003年9月开始,2006年1月初提前终止。研究采用2×2析因设计对患者进行随机分配。

结果

到2005年底,已收到13698例研究患者的完整随访记录。已观察到使用前房注射头孢呋辛有如此明显的有益效果,以至于大家一致认为继续该研究并等待所有随访程序完成后再报告这一重要结果是不道德的。如果考虑报告的眼内炎总病例数,未接受头孢呋辛预防的治疗组观察到的发生率(6862例患者中有23例)几乎是接受该治疗组(6836例患者中有5例)的5倍(优势比[OR]为4.59;95%置信区间[CI]为1.74 - 12.08;P = 0.002)。如果仅考虑经证实因感染导致的病例,未接受头孢呋辛的治疗组发生率高出5倍多(OR为5.32;95%CI为1.55 - 18.26;P = 0.008)。虽然围手术期使用左氧氟沙星滴眼液作为预防措施也与术后眼内炎观察到的发生率降低有关,但这种效果较小且无统计学意义,无论是计算总报告病例数还是仅计算经证实因感染导致的病例数。由于并非所有随访程序都已完成,可能会报告更多眼内炎病例;然而,预计这不会改变主要结论。尽管如此,预计所有患者随访程序的成功完成将使研究总数增加到约16000例。

结论

手术时前房注射头孢呋辛显著降低了白内障手术后发生眼内炎的风险。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验